Medspa accelerates overseas development and looks to the UK

A target of 65 million euros in revenues in 2026: Medspa, a company founded in 2006 by a family that has always been involved in the pharmaceutical and aesthetic medicine fields and has developed the functional cosmetics brand Miamo and the Nutraiuvens line of food supplements, has set itself the target of 65 million euros in revenues in 2026. An ambitious goal, but one that follows a 2025 archived with an increase in turnover of 23% to 53 million. The result was accompanied by the progressive consolidation of the organisational structure and the evolution of internal processes, with a strengthening of control and economic-financial planning. In recent years, Medspa has worked to make its operating model more scalable, measurable, and consistent with sustainable margin targets.

The 2026 investment plan is based on three main lines: organisational strengthening, multi-channel commercial development and international acceleration. A central chapter of the plan concerns international expansion: after the launch of the presidium in Switzerland, the group's first strategic foreign market, the company is targeting the UK with the Miamo brand.

"2025 was a year of consolidation and structuring," emphasises Giovanni D'Antonio, CEO of Medspa. "We worked to strengthen our industrial base, processes and financial discipline, which are fundamental elements to sustain balanced growth. The 2026 target is ambitious but consistent with the path we have taken: we intend to continue to grow while maintaining cost control, attention to margins and investment capacity, consolidating our position also on international markets'.